Literature DB >> 8620957

Elevated exhaled nitric oxide in patients with hepatopulmonary syndrome.

G Cremona1, T W Higenbottam, V Mayoral, G Alexander, E Demoncheaux, C Borland, P Roe, G J Jones.   

Abstract

The hypoxaemia of hepatopulmonary syndrome, seen in severe chronic liver dysfunction, occurs as a result of precapillary pulmonary arterial dilatation and arteriovenous communications. These abnormalities contribute to the mismatch between ventilation and perfusion, and the right to left blood flow shunting. Nitric oxide (NO) is a powerful vasodilator concerned with the regulation of pulmonary vascular tone in man. Using a chemiluminescence analyser, we have measured endogenously produced NO in the exhaled air of three patients with the hepatopulmonary syndrome, six normoxaemic cirrhotic patients and six healthy volunteers. The subjects breathed NO-free air throughout the measurements. The molar rate of production of exhaled NO was raised almost threefold in the patients with hepatopulmonary syndrome compared with normal volunteers and with normoxaemic cirrhotic patients. Hypoxia per se, achieved in the normal volunteers by breathing a hypoxic gas mixture, reduced rather than increased the exhaled NO. One hepatopulmonary syndrome patient received an orthotopic liver transplant and achieved normoxaemia after 3 months. The exhaled NO also returned to normal. Increased pulmonary production of NO could contribute to the development of the hepatopulmonary syndrome.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8620957     DOI: 10.1183/09031936.95.08111883

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  35 in total

1.  Cardiopulmonary effects of nitric oxide inhalation and methylene blue injection in hepatopulmonary syndrome.

Authors:  V Jounieaux; O Leleu; I Mayeux
Journal:  Intensive Care Med       Date:  2001-06       Impact factor: 17.440

Review 2.  Hepatopulmonary syndrome.

Authors:  M B Fallon; G A Abrams
Journal:  Curr Gastroenterol Rep       Date:  2000-02

Review 3.  Hepatopulmonary syndrome: What we know and what we would like to know.

Authors:  Israel Grilo-Bensusan; Juan Manuel Pascasio-Acevedo
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

Review 4.  Portopulmonary hypertension.

Authors:  Michael Halank; Ralf Ewert; Hans-Juergen Seyfarth; Gert Hoeffken
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

5.  The role of receptor tyrosine kinase activation in cholangiocytes and pulmonary vascular endothelium in experimental hepatopulmonary syndrome.

Authors:  Wenli Yang; Junlan Zhang; Bingqian Hu; Wei Wu; Julie Venter; Gianfranco Alpini; Michael B Fallon
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-11-07       Impact factor: 4.052

Review 6.  [Pulmonary complications in liver diseases].

Authors:  T Horvatits; A Drolz; K Rutter; S Kluge; V Fuhrmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-04-26       Impact factor: 0.840

7.  Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease.

Authors:  Kari E Roberts; Steven M Kawut; Michael J Krowka; Robert S Brown; James F Trotter; Vijay Shah; Inga Peter; Hocine Tighiouart; Nandita Mitra; Elizabeth Handorf; James A Knowles; Steven Zacks; Michael B Fallon
Journal:  Gastroenterology       Date:  2010-03-24       Impact factor: 22.682

8.  A rare case of congenital complex pulmonary AV fistula.

Authors:  Akshyaya Pradhan; Rashi Khare; Rishi Sethi
Journal:  BMJ Case Rep       Date:  2014-10-17

Review 9.  Potential Clinical Targets in Hepatopulmonary Syndrome: Lessons From Experimental Models.

Authors:  Sarah Raevens; Michael B Fallon
Journal:  Hepatology       Date:  2018-11       Impact factor: 17.425

Review 10.  Platypnea-orthodeoxia syndrome : Orthostatic dyspnea and possible pathophysiological substrates.

Authors:  R De Vecchis; C Baldi; C Ariano; A Giasi; C Cioppa
Journal:  Herz       Date:  2016-09-12       Impact factor: 1.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.